

## Corrigendum to: LY6K promotes glioblastoma tumorigenicity via CAV-1–mediated ERK1/2 signaling enhancement

This is a corrigendum to: Namratha G Sastry, Xuechao Wan, Tianzhi Huang, Angel A Alvarez, Rajendra P Pangeni, Xiao Song, Charles David James, Craig M Horbinski, Cameron W Brennan, Ichiro Nakano, Bo Hu, Shi-Yuan Cheng, LY6K promotes glioblastoma tumorigenicity via CAV-1–mediated ERK1/2 signaling enhancement, *Neuro-Oncology*, Volume 22, Issue 9, September 2020, Pages 1315–1326, <https://doi.org/10.1093/neuonc/noaa032>


In April 2024, concerns were raised on PubPeer about Figure 3A. The Journal subsequently contacted the corresponding author for an explanation. Following the authors' checks, the Journal has agreed that they may amend the immunoblot data for GSC30 (third and fourth column on the right) shown

in Fig. 3A, which were found to be erroneous. In the originally published version, the lane of p-ERK1/2 was mistakenly used twice.

In the corrected Figure 3A, the authors have replaced the data from the two rightmost columns using the original data from experiments that were performed during the same period as the original data were produced. The new figure panel is shown here.

The authors and editors agree that the new data do not impact the results or conclusions of the published article, and the authors have apologized for mistakenly uploading the wrong image originally.

The corrected Figure 3 is given below:



These details have been corrected only in this corrigendum to preserve the published version of record.